CA
NZ
UK
AU
IND
US
DigitalOcean Holdings Inc. (NYSE: DOCN) has signaled a robust quarter, forecasting record financial metrics for Q2 2026. The cloud infrastructure provider’s preliminary results highlight significant growth in key performance indicators, driving investor confidence.
Brookfield Asset Management (NYSE: BAM) has scheduled its second-quarter 2026 earnings call for August 5. The event will provide investors with insights into the company’s financial performance and strategic outlook. Details were formally disclosed in a press release issued on July 6.
AbbVie reported preliminary figures for the quarter ended June 30, 2026, and revised its earnings outlook. The update revises both full-year and Q2 guidance, offering investors a clearer view of earnings potential amid ongoing strategic initiatives in the pharmaceutical sector.
Tvardi Therapeutics (NASDAQ: TVRD) issued a corporate announcement presenting results from the first-in-human study of its investigational candidate TTI‑109. The data validate the drug’s engineered prodrug architecture and provide early signs of its potential.
U.S. Physical Therapy (NYSE: USPH) has broadened its outpatient footprint by adding a 12‑location physical therapy provider. The transaction, recently completed, reinforces the company’s presence in the expanding rehabilitation services market and aligns with its growth strategy that emphasizes selective acquisitions.
Vaxart Inc. (OTC: VXRT) announced topline safety findings from its Phase 2b clinical trial, indicating that the oral COVID‑19 vaccine candidate did not raise serious safety flags. The investigation contrasted the pill formulation with an authorized mRNA vaccine within an approximately 400‑participant sentinel safety …
Vera Therapeutics (NASDAQ: VERA) has achieved a major regulatory milestone with the U.S. Food and Drug Administration’s accelerated approval of its drug TRUTAKNA. The decision highlights the company’s growing influence in addressing serious kidney disorders that have historically had limited therapeutic options.
A significant financial partnership is on the horizon for Semnur Pharmaceuticals, Inc. As iHolding Group LLP has initiated plans for a substantial investment. This agreement, formalized through a binding term sheet on July 3, 2026, sets the stage for iHolding to purchase $100 million …
Splash Beverage Group (NYSE American: SBEV) has entered the pharmaceutical sector with a licensing agreement for CannEpil, an epilepsy treatment. The move reflects a strategic shift for the company as it broadens its business focus beyond beverages into healthcare.
Splash Beverage Group Inc. (NYSE American: SBEV) has entered into an Exclusive License Agreement with Argent Biopharma Limited, acquiring the rights to the pharmaceutical product CannEpil. This product is designed for the treatment of epilepsy and related neurological conditions in humans. The healthcare sector …
Please wait processing your request...